Following Pfizer's quarterly earnings release, UCB confirms that Zyrtec continues to strengthen its leadership position as the number one most prescribed branded antihistamine in the US in new prescriptions. The US in-market sales of Zyrtec have reached USD 1,362 million during the year 2005, showing a 6 % increase against the same period in 2004.
